Last updated: May 7, 2026
Who manufactures hydrocodone polistirex (API and/or drug product)?
Hydrocodone polistirex is sold as a controlled-release, polystyrene-based polymer complex of hydrocodone. The supply chain is split between (1) polymer-complex API producers and (2) finished-dose manufacturers that formulate into syrup/suspension strengths.
What is consistently visible in commercial trade channels
- Suppliers typically operate either as API manufacturers (polymer complex of hydrocodone) or as finished-dose manufacturers (controlled-release hydrocodone polistirex + co-actives, depending on the product).
- Distribution into many markets is usually channelized through specialty wholesalers due to hydrocodone’s regulatory controls.
Practical supplier categories to target
- Controlled-substance API manufacturers with DEA registration (for the US) and equivalent national licensing elsewhere.
- Contract manufacturing organizations (CMOs) that already handle opioid controlled-release polymer formulations and can support controlled-release process validation, analytical method transfer, and stability programs.
- Finished-dose manufacturers if your goal is product supply rather than API-only procurement.
Who manufactures chlorpheniramine polistirex (API and/or drug product)?
Chlorpheniramine polistirex is a controlled-release polymer complex of chlorpheniramine. Like hydrocodone polistirex, it is commonly supplied either as a complex API or embedded in a finished controlled-release combination product.
What the market structure typically looks like
- Chlorpheniramine polistirex suppliers are usually the same types of firms as hydrocodone polistirex: licensed controlled-release API makers and/or finished-dose manufacturers handling solid or liquid controlled-release products depending on the dosage form.
Practical supplier categories to target
- API producers that can supply polymer complex material under GMP, with characterization for drug loading and release profile.
- CMOs capable of controlled-release formulation and long-cycle release testing.
What suppliers exist for the combination of HYDROCODONE POLISTIREX + CHLORPHENIRAMINE POLISTIREX?
The combination indicates a finished-dose product pathway where one party typically supplies:
- both complexes (directly or through upstream API supply), or
- one complex internally and sources the other, or
- the finished formulation under private label or contract manufacturing.
Supplier identification requirement (critical)
To provide a precise supplier list (company names tied to each API or the finished combination), the answer must map:
- the exact marketed products (including strength and dosage form),
- the registered manufacturers in the target jurisdiction(s),
- and the approved manufacturing sites for the specific API complexes.
This mapping requires product registration and label-manufacturer data that is not contained in the prompt.
What must be confirmed in supplier qualification packages for these two polistirex APIs?
Even without naming specific suppliers, the qualification checklist for these polymer complexes is standard and should be demanded from any candidate supplier.
API-level requirements (both complexes)
- GMP manufacturing status (DMF/ASMF coverage where applicable).
- Defined polymer complex specifications, including:
- drug loading range,
- particle/complex characterization,
- identity and impurity profiles specific to the polymer complex matrix.
- Controlled-release performance evidence, typically referencing:
- in vitro release method and acceptance criteria,
- batch-to-batch consistency.
Regulatory handling requirements
- Controlled substance licensing for hydrocodone-containing supply (DEA registration in the US or equivalent regime elsewhere).
- Import/export compliance and secure logistics.
- Documentation pack including CoA, GMP certificate, and full analytical report.
Finished-dose requirements (if sourcing a finished combination product)
- Specifications for syrup/suspension or tablet format used in the marketed product.
- Stability program aligned with controlled-release behavior.
- Container closure suitability for polymer-based controlled-release suspensions.
Market-facing supplier strategy (actionable without naming individual firms)
If the business goal is supply assurance, the correct sourcing approach is typically:
- Shortlist API manufacturers and CMOs separately for each complex (hydrocodone polistirex and chlorpheniramine polistirex), then verify they can supply together in a coordinated schedule.
- If the goal is to secure end-product supply, shortlist finished-dose manufacturers that already make the hydrocodone + chlorpheniramine combination controlled-release format.
- Run a qualification sequence that starts with right-to-manufacture (license), then right-to-test (analytical capability), then right-to-release (controlled-release specs).
Key Takeaways
- Hydrocodone polistirex and chlorpheniramine polistirex are controlled-release polymer complex products; suppliers usually split into API makers and finished-dose manufacturers/CMOs.
- Any supplier list that names specific companies must be tied to the exact marketed product and jurisdictional registration, including manufacturing site data.
- Supplier qualification should prioritize GMP, polymer complex specifications, controlled-release performance, and controlled-substance licensing for hydrocodone.
FAQs
1) Can I source both polistirex APIs from a single supplier?
Often, but it depends on whether the supplier manufactures both complexes or acts as a CMO that formulates a finished combination product. Many supply structures still require at least one upstream API source per complex.
2) Is polymer-complex API harder to qualify than standard APIs?
Yes. Specs usually include polymer-complex identity and drug loading plus controlled-release performance criteria, which require method validation and batch comparability.
3) What documentation should I request for these APIs?
CoA plus the full analytical report, GMP certificate, detailed specifications, method descriptions, stability data, and documentation that covers polymer-complex characterization and impurities.
4) What is the biggest gating factor for hydrocodone polistirex supply?
Controlled-substance compliance: hydrocodone requires licensing and secure handling across manufacturing, distribution, and import/export.
5) If I’m buying finished combination product, what changes in supplier selection?
You prioritize manufacturing authorization, release and stability programs for the specific dosage form, and packaging/labeling compliance over raw polymer complex characterization depth.
References
[1] FDA. “Drug Master Files (DMF).” U.S. Food and Drug Administration. https://www.fda.gov/drugs/drug-master-files-dmf
[2] FDA. “Controlled Substances.” U.S. Food and Drug Administration. https://www.fda.gov/drugs/drug-approvals-and-databases/controlled-substances
[3] DEA. “Diversion Control Division.” U.S. Drug Enforcement Administration. https://www.dea.gov/diversion-control
